Treatment of Cancer Using Anti-HLA-G/Anti-CD3 Bispecific Antibody and 4-1BB Agonist
Summary
The USPTO published patent application US20260092118A1 by Hoffmann-La Roche Inc., covering a method for treating cancer using an anti-HLA-G/anti-CD3 bispecific antibody in combination with a 4-1BB (CD137) agonist. The application (No. 19325175) was filed September 10, 2025, and lists Meher Majety, Carina Hage, and Johannes Sam as inventors. This publication represents an early-stage intellectual property filing for a bispecific antibody-based cancer therapy.
What changed
Hoffmann-La Roche Inc. filed a patent application (US20260092118A1) with the USPTO for a cancer treatment method combining an anti-HLA-G/anti-CD3 bispecific antibody with a 4-1BB (CD137) agonist. The invention falls under CPC classifications including C07K 16/2833 (bispecific antibodies) and A61P 35/00 (antineoplastic agents). The application was published April 2, 2026, with a filing date of September 10, 2025.
This is a patent publication notice, not a regulatory requirement. Pharmaceutical companies and biotechnology firms researching bispecific antibody therapies or 4-1BB agonists for cancer treatment should review this application to assess potential freedom-to-operate implications or identify opportunities for licensing discussions. There is no compliance deadline or penalty provision associated with this publication.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREATMENT OF CANCER USING AN ANTI-HLA-G/ANTI-CD3 BISPECIFIC ANTIBODY AND A 4-1BB (CD137) AGONIST
Application US20260092118A1 Kind: A1 Apr 02, 2026
Assignee
Hoffmann-La Roche Inc.
Inventors
Meher MAJETY, Carina HAGE, Johannes SAM
Abstract
The present invention relates to the treatment of cancer, in particular to the treatment of cancer using an anti-HLA-G/anti-CD3 bispecific antibody and a 4-1BB (CD137) agonist.
CPC Classifications
C07K 16/2833 A61P 35/00 C07K 14/4705 C07K 16/2809 C07K 16/40 A61K 38/00 A61K 2039/505 C07K 2317/31 C07K 2317/33 C07K 2317/522 C07K 2317/55 C07K 2317/565 C07K 2317/71 C07K 2319/00
Filing Date
2025-09-10
Application No.
19325175
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.